Benznidazole

	WikiDoc Resources for Benznidazole
Articles
Most recent articles on Benznidazole Most cited articles on Benznidazole Review articles on Benznidazole Articles on Benznidazole in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Benznidazole Images of Benznidazole Photos of Benznidazole Podcasts & MP3s on Benznidazole Videos on Benznidazole
Evidence Based Medicine
Cochrane Collaboration on Benznidazole Bandolier on Benznidazole TRIP on Benznidazole
Clinical Trials
Ongoing Trials on Benznidazole at Clinical Trials.gov Trial results on Benznidazole Clinical Trials on Benznidazole at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Benznidazole NICE Guidance on Benznidazole NHS PRODIGY Guidance FDA on Benznidazole CDC on Benznidazole
Books
Books on Benznidazole
News
Benznidazole in the news Be alerted to news on Benznidazole News trends on Benznidazole
Commentary
Blogs on Benznidazole
Definitions
Definitions of Benznidazole
Patient Resources / Community
Patient resources on Benznidazole Discussion groups on Benznidazole Patient Handouts on Benznidazole Directions to Hospitals Treating Benznidazole Risk calculators and risk factors for Benznidazole
Healthcare Provider Resources
Symptoms of Benznidazole Causes & Risk Factors for Benznidazole Diagnostic studies for Benznidazole Treatment of Benznidazole
Continuing Medical Education (CME)
CME Programs on Benznidazole
International
Benznidazole en Espanol Benznidazole en Francais
Business
Benznidazole in the Marketplace Patents on Benznidazole
Experimental / Informatics
List of terms related to Benznidazole

Benznidazole
Clinical data
Trade names	Rochagan, Radanil
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Oral
ATC code	P01CA02 (WHO) ;
Pharmacokinetic data
Bioavailability	High
Metabolism	Hepatic
Elimination half-life	12 hours
Excretion	Renal and fecal
Identifiers
	IUPAC name N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide;
CAS Number	22994-85-0 ;
PubChem CID	31593;
ChemSpider	29299 ;
UNII	YC42NRJ1ZD;
KEGG	D02489 ;
ChEMBL	ChEMBL110 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C12H12N4O3
Molar mass	260.249 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=[N+]([O-])c1nccn1CC(=O)NCc2ccccc2;
	InChI InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17) ; Key:CULUWZNBISUWAS-UHFFFAOYSA-N ;
(verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Benznidazole (INN, formerly marketed by Hoffman-La Roche under the trade names Rochagan and Radanil) is an antiparasitic medication used in the treatment of Chagas disease. Its mechanism of action is the production of free radicals, to which the Trypanosoma cruzi is particularly sensitive given its reduced detoxification capabilities.^[1] Roche donated the technology and rights to produce benznidazole to the Brazilian government.^[2]

It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.^[3]

Medical uses

Benznidazole has a significant activity during the acute phase of the disease, with a therapeutical success rate of up to 80%. Its curative capabilities during the chronic phase are, however, limited. Some studies have found parasitologic cure (a complete elimination of T. cruzi from the body) in pediatric and young patients during the early stage of the chronic phase, but overall failure rate in chronically infected individuals is typically above 80%.^[1]

However, some studies indicate treatment with benznidazole in chronic patients, even if incapable of producing parasitologic cure, carries a significative reduction of occurrence of electrocardiographic changes and a delayed worsening of the clinical condition of the patient.^[1]

Benznidazole has proven to be effective in the treatment of reactivated T. cruzi infections caused by immunosuppression, such as AIDS patients or those under immunosuppressive therapy related to organ transplants.^[1]

Side effects

The side effects most commonly associated with benznidazole therapy are rash and gastrointestinal symptoms such as nausea. Rarely, peripheral neuropathy may present after prolonged treatment.

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 Urbina, Julio A. "Nuevas drogas para el tratamiento etiológico de la Enfermedad de Chagas" (in Spanish). Retrieved March 24, 2012.
↑ http://www.itg.be/evde/04_Chagas_diseasep12.htm
↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.

External links

"Rochagan [Patient Information]" (PDF) (in português). Hoffmann-La Roche. Retrieved 2006-11-27.

Template:Excavata antiparasitics

This antimicrobial-related article is a stub. You can help Wikipedia by expanding it.

[urbina-1] 1.0 ^1.1 ^1.2 ^1.3 Urbina, Julio A. "Nuevas drogas para el tratamiento etiológico de la Enfermedad de Chagas" (in Spanish). Retrieved March 24, 2012.

[2] ttp://www.itg.be/evde/04_Chagas_diseasep12.htm

[3] "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.

[1]

[2]

[3]